Empagliflozin receives FDA approval for use in adults with heart failure
medwireNews: The sodium-glucose cotransporter 2 inhibitor empagliflozin may now be used to reduce the risk for cardiovascular death and heart failure hospitalization in adults with heart failure and reduced ejection fraction in the USA.
Its other approved uses are to reduce glucose levels in adults with type 2 diabetes and to reduce the risk for cardiovascular death in those who also have established cardiovascular disease.
FDA approval for the expanded indication follows the 2020 publication of the EMPEROR-Reduced trial, which found a significant 25% reduction in the risk for death from cardiovascular causes or hospitalization for heart failure with empagliflozin versus placebo in this patient group.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group